Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• the invention relates to the use of parts or an extract of Amaranthus blitoides.
• Amaranthus blitoides is a plant originally from South and Central America.
• Amaranthus blitoides was and is used in Central America and in the Balkans in the form of salads and as an additive to other foods and as an additive to animal feed. In the natural food trade, leaves and seeds of this plant can be found in mueslis or cooked into groats.
• Amaranthaceae are also used for the production of food colors.
• a use in the pharmaceutical field is known from DE 101 13 328 AI, in which plant coagulates inter alia also from amaranthaceae. can be used with various plant extracts for the treatment of menstrual disorders in particular.
• Various substances such as local anesthetics, glucocorticoids, anaigetics and astringents, are used to treat inflammatory diseases. These substances and their preparations are administered either locally, orally or as an injection, with various ne application forms can be combined. It can also be combined with antimicrobial substances (chemotherapeutic agents, antibiotics).
• the use of parts or an extract of Amaranthus blitoides is provided for the production of a pharmaceutical preparation.
• Amaranthus blitoides in dried form contains various flavonoids, tannin and vitamin C in a concentration of 135 - 185 mg% and the following ingredients:
• Amaranthus blitoides are preferably aqueous extracts because they can be easily prepared - even by the patient himself in the form of tea. "But it can other extracts such as alcoholic, alcoholic-aqueous extracts or dry extracts can also be used.
• parts of Amaranthus blitoides, liquid extracts of Amaranthus blitoides, which are concentrated or lyophilized to dryness or dry, can be processed into tea, solutions, dragees, tablets or ointments which, according to the invention, are conventional carriers in addition to the components of Amaranthus blitoides - May contain auxiliary substances.
• the preparations according to the invention are accordingly used orally, topically, locally or parenterally.
• the pharmaceutical preparations according to the invention are suitable for the treatment of inflammatory diseases.
• a dry extract from Amaranthus blitoides has a reaction time prolonging effect in the hot plate test after oral administration. This is dose and time dependent.
• the intensity of action is highest after administration of 33 and 100 mg / kg. Amaranthus blitoides works in this dose range with a 70% inhibition of the reaction time just as strongly as the method-specific reference drug Metamizol (see Table 1). These doses also correspond to those used in humans.
• Oral extracts from Amaranthus blitoides are initially unremarkable in the mouse behavior test. Slightly sedative effects can be demonstrated in doses above 100 mg / kg. The effects differ significantly from chlorpromazine and atropine. The outstanding effect in this model is shown by the Haffner phenomenon, which is characteristic of analgesic effects.
• Amaranthus blitoides extracts have been studied in 100 patients with acute or chronic urinary tract infection (pyelonephritis, cystitis, stone formation) or prostate. Before the start of therapy, all patients underwent complete laboratory analyzes of blood and urine, and a sperm culture was established for prostate diseases.
• the infection was mostly caused by E. coli and Proteus mirabilis, while in 10 cases Pseudomonas was isolated. Staphylococcus aureus was dominant in the sperm cultures obtained.
• Treatment was performed on all patients at who was given an extract equivalent to 5 g of dry Amaranthus blitoides drug every 6 hours.
• the cultures were found to be sterile or the number of microorganisms was significantly reduced compared to the state before therapy.
• the sperm cultures also improved in 10 patients with prostate diseases.
• Herpes simplex was also successfully used in an ointment containing the extract of Amaranthus blitoides.

Landscapes

• Health & Medical Sciences (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Biotechnology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Botany (AREA)
• Pain & Pain Management (AREA)
• Engineering & Computer Science (AREA)
• Medical Informatics (AREA)
• Rheumatology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Alternative & Traditional Medicine (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Epidemiology (AREA)
• Medicines Containing Plant Substances (AREA)
• Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
• Cosmetics (AREA)

Priority Applications (3)

Applications Claiming Priority (6)

Publications (1)

Family

ID=33544856

Family Applications (1)

Country Status (5)

Cited By (2)

Citations (3)

• 2004
  • 2004-06-09 AT AT04739741T patent/ATE428435T1/de active
  • 2004-06-09 ES ES04739741T patent/ES2325992T3/es not_active Expired - Lifetime
  • 2004-06-09 EP EP04739741A patent/EP1641477B1/de not_active Expired - Lifetime
  • 2004-06-09 WO PCT/EP2004/006235 patent/WO2004112812A1/de active Application Filing
  • 2004-06-09 DE DE502004009359T patent/DE502004009359D1/de not_active Expired - Lifetime

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events